Last updated 2026-07-20
- Acquired by Roche for $3.5B, Oct 2025
- Raised $60M Series A led by OrbiMed, Sep 2018
- Raised Follow-on PO, Dec 2024
Total raised
$60.0M
Last: A Round 2018-10
Stage
Acquired
Founded
2018
Headcount
93
HQ
San Francisco, United States
Sector
Health Tech & Life Sciences
About
89bio is a clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat patients with liver and cardiometabolic diseases. The company's lead product candidate, pegozafermin (formerly BIO89-100), is an investigational glycoPEGylated FGF21 analog being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). 89bio was founded in Israel in 2018 and is currently headquartered in the U.S., with an R&D center in Israel.
Funding history · 8 rounds · $60.0M total
2024-12
Follow-on PO
Undisclosed
2024-10
Follow-on PO
Undisclosed
2023-11
Follow-on PO
Undisclosed
2023-02
Follow-on PO
Undisclosed
2022-05
Follow-on PO
Undisclosed
2020-06
Follow-on PO
Undisclosed
2019-10
Follow-on PO
Undisclosed
2018-09
A Round
$60.0M
★ OrbiMed★ Pontifax★ Longitude Capital★ RA Capital Management
Headcount over time
From 63 (2023-07) to 147 (2026-03) · +84 (+133%) · 16 points · source: Finder history + radar grounding
Q&A
- What is 89bio's primary focus?
- 89bio is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for liver and cardio-metabolic diseases.
- What is 89bio's lead product candidate?
- 89bio's lead product candidate is pegozafermin (BIO89-100), an investigational glycopegylated FGF21 analog.
- What conditions is pegozafermin being evaluated for?
- Pegozafermin is currently being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).
- When was 89bio founded?
- 89bio was founded in January 2018.
- What is 89bio's current market capitalization?
- 89bio's market capitalization is $2,203,627,632 USD.
- What is the total amount of funding 89bio has raised?
- 89bio has raised a total of $1,146,000,000 USD.
- When was 89bio's last funding round and who were the investors?
- 89bio's last funding round occurred in October 2018, with investors including RA Capital Management and Pontifax.
- What is the current status of 89bio?
- 89bio is currently active and was acquired by Roche in September 2025.
Team · 5
Michal Ayalon
Founder · Head of R&D
Ram Waisbourd
Founder · COO and Chief Business Officer
Michael Hayden
Founding Board Member
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2B
Highlights
Patents
Tags
biopharmaceuticaldiabetespharmaceuticalsbiotechnologylife-sciencespatientsgastroenterology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | 89bio.com |
|---|---|
| linkedin.com/company/54350802 | |
| Wikipedia | he.wikipedia.org/wiki/89%D7%91%D7%99%D7%95 |
| Wikidata | wikidata.org/wiki/Q136365899 |
Identifiers & details
| Legal name | 89bio, Inc. |
|---|---|
| Founded | 2018-1 |
| Employees (exact) | 93 |
| Wikidata QID | Q136365899 |
Acquisitions & public offerings
Acquired by Roche 2025-10 $3.5B
Radar intelligence
Patents
| EPO | 13 |
|---|
Publications (Crossref)
| Works | 8 |
|---|
Web history (Wayback)
| Domain | 89bio.com |
|---|
Wikidata
| QID | Q136365899 |
|---|
Certificate / subdomain footprint
| Subdomains | 4 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515789352 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2018-01-31 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2023 |
| Active charges / liens | 0 |
| Registry events | 6 — charge (2), violation (1), people (3) |
| Registered address | אופנהיימר 4 רחובות |
Recent registry events
| Date | Event |
|---|---|
| 2025-10-30 | סילוק שעבוד |
| 2025-10-30 | סילוק שעבוד |
| 2026-06-25 | עדכון הפרה |
| 2026-01-20 | עדכון בעלי תפקידים |
| 2026-03-11 | עדכון דירקטורים-הוספת דירקטור |
| 2026-03-11 | עדכון דירקטורים-הסרת דירקטור |